<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455362</url>
  </required_header>
  <id_info>
    <org_study_id>022/13 V.3.2.3</org_study_id>
    <nct_id>NCT02455362</nct_id>
  </id_info>
  <brief_title>Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Multi-site, Double-blind, Parallel Arm, Block Randomised, Placebo Controlled, Factorial Phase III Study of Opioids for Chronic Refractory Breathlessness in People With Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flinders University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flinders University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breathlessness, the sensation of breathing discomfort, is a major problem in people with&#xD;
      chronic obstructive pulmonary disease (COPD). Breathlessness that persists despite optimal&#xD;
      management of the underlying disease(s) is said to be refractory.&#xD;
&#xD;
      Preliminary evidence suggests that a small, regular dose of morphine helps to reduce safely&#xD;
      the sensation of breathlessness. However, this research on morphine for breathlessness has&#xD;
      not defined the best way to adjust the dose of the medication, or refined which people are&#xD;
      most likely to have benefit, no response or side effects.&#xD;
&#xD;
      This is a randomized, double-blind phase III trial in people with COPD and significant&#xD;
      refractory breathlessness, which will explore several important questions:&#xD;
&#xD;
        -  Are regular, low dose opioids (morphine) at four possible doses over 3 weeks more&#xD;
           effective than placebo medication (containing no active ingredient) at improving&#xD;
           breathlessness?&#xD;
&#xD;
        -  Does the medication have any effect on daily activity, breathlessness, and quality of&#xD;
           life?&#xD;
&#xD;
        -  What are the common side effects of this intervention?&#xD;
&#xD;
        -  Does the benefit from the drug outweigh the side effects it produces?&#xD;
&#xD;
        -  Are there specific characteristics of people who are more likely to receive benefit from&#xD;
           sustained release morphine?&#xD;
&#xD;
      Participants will be allocated to receive three weeks of morphine sulfate (and laxative,&#xD;
      docusate with senna), or placebo (and placebo laxative). The dose of morphine may be&#xD;
      increased each week for weeks two and three. All medicines will appear the same (blinded) and&#xD;
      neither the doctor nor the participant will know which medication the participant is&#xD;
      receiving.&#xD;
&#xD;
      Participants will have a medical interview, physical examination to collect some general&#xD;
      health information, and baseline measurements including; daily activity, symptoms, and&#xD;
      quality of life. A small amount of blood may be required to check eligibility. Further blood&#xD;
      samples may be taken at week 1 and 3 to enable testing on how individuals respond to opioids,&#xD;
      further consent will be obtained for these samples. Data on benefits, side effects, and&#xD;
      medical care will be collected during comprehensive weekly visits. Participants will also&#xD;
      fill out a simple diary twice daily for weeks one to three of the study, and for one day each&#xD;
      week during an optional 3 month extension stage.&#xD;
&#xD;
      The outcome of this study may enable better management of symptoms and activity in people&#xD;
      COPD with medicines that are shown to be effective and safe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Three hundred thousand (300,000) Australians are breathless at rest or on minimal&#xD;
      exertion, often for years, despite optimal treatment of the underlying cause(s). This&#xD;
      includes more than 70,000 people who are too breathless to leave their homes often for long&#xD;
      periods of time. Underlying causes for such severe and ongoing breathlessness include chronic&#xD;
      obstructive pulmonary disease (COPD), interstitial lung disease, heart failure,&#xD;
      neurodegenerative diseases such as motor neurone disease and cachexia from any cause. The&#xD;
      prevalence of chronic refractory breathlessness will continue to increase as the population&#xD;
      ages because the chronic progressive diseases where breathlessness is common are increasing&#xD;
      in prevalence. Nearly one half of all people experience distressing breathlessness during the&#xD;
      last year of life.&#xD;
&#xD;
      The American Thoracic Society defines breathlessness as &quot;a subjective experience of breathing&#xD;
      discomfort that consists of qualitatively distinct sensations that vary in intensity&quot;. The&#xD;
      term 'dyspnoea' is used interchangeably with breathlessness, shortness of breath, breathing&#xD;
      difficulty and laboured breathing.&#xD;
&#xD;
      Internationally, no medication is registered for the symptomatic reduction of chronic&#xD;
      refractory breathlessness despite recommendations from the American Thoracic Society, the&#xD;
      American College of Physicians, the Canadian Thoracic Society and the American College of&#xD;
      Chest Physicians that regular, low-dose morphine is the evidence-based pharmaceutical option.&#xD;
&#xD;
      Aim: To enhance the evidence base for the pharmacological treatment of chronic refractory&#xD;
      breathlessness using potential therapies compared to placebo.&#xD;
&#xD;
      Primary objective: To compare the difference of the net clinical effect (benefits and side&#xD;
      effects) on chronic refractory breathlessness in people with chronic obstructive pulmonary&#xD;
      disease (COPD) taking once daily, sustained release morphine at two different doses when&#xD;
      compared to placebo.&#xD;
&#xD;
      Secondary objectives.&#xD;
&#xD;
        1. Are regular, low dose oral opioids safe, including when the dose is titrated upwards, in&#xD;
           a population of people with refractory breathlessness and COPD?&#xD;
&#xD;
        2. Do people whose breathlessness is helped by regular, low dose oral morphine get&#xD;
           additional benefit by further increasing the dose of morphine?&#xD;
&#xD;
        3. Over what period of time does benefit continue to increase once a dose level with&#xD;
           benefit is achieved?&#xD;
&#xD;
        4. What percentage of people derive clinically significant benefit at each of four dosing&#xD;
           levels over and above placebo?&#xD;
&#xD;
        5. At the lower doses, is there evidence that any benefit does not last the full 24 hours?&#xD;
           (end-of-dose failure)&#xD;
&#xD;
        6. Can we predict response, benefit and side effects from baseline demographic and clinical&#xD;
           data&#xD;
&#xD;
        7. Does the treatment of breathlessness with regular, low dose morphine have any effect on&#xD;
           general health status and quality of life?&#xD;
&#xD;
        8. Determine if there is a change in activities of daily living in those treated with&#xD;
           opioids when compared to placebo.&#xD;
&#xD;
        9. Assess any effects of each treatment on anxiety and depression.&#xD;
&#xD;
       10. Understand the longer term benefits and side effects from sustained release morphine in&#xD;
           people with COPD when compared to placebo.&#xD;
&#xD;
       11. Do participants, while still blinded, have any preference at the end of the three week&#xD;
           study?&#xD;
&#xD;
      Sub-studies&#xD;
&#xD;
        1. Identify pharmacokinetic and pharmacodynamic parameters that may help to predict which&#xD;
           individuals will achieve the greatest benefit in week one of therapy (8mg/day,&#xD;
           16mg/day).&#xD;
&#xD;
        2. Identify pharmacogenomic variations in opioid receptors and signaling that may help to&#xD;
           predict clinical response (benefit, side effects or no response).&#xD;
&#xD;
        3. Study the effect on sleep in people participating in the study&#xD;
&#xD;
        4. Compare the within trial incremental cost and cost effectiveness of the therapy&#xD;
&#xD;
        5. Evaluate any changes in total testosterone from baseline to the end of the three month&#xD;
           extension.&#xD;
&#xD;
      Null hypothesis: In people who have COPD with refractory breathlessness, there is no&#xD;
      difference in breathlessness intensity with the addition of regular, low dose oral sustained&#xD;
      release morphine when compared to placebo.&#xD;
&#xD;
      Alternative hypothesis: The addition of regular, low dose oral sustained release morphine&#xD;
      reduces the intensity of breathlessness in people with COPD and that this occurs safely.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A five stage, national, multi-site, double-blind, parallel arm, block randomised, placebo&#xD;
      controlled factorial (dose increment) phase III study of opioids for chronic refractory&#xD;
      breathlessness in people with COPD:&#xD;
&#xD;
      Stage 0 - baseline (2 days); Stage 1 - randomisation #1 (1 week); Stage 2 - randomisation #2&#xD;
      (1 week); Stage 3 - randomisation #3 (1 week); and Stage 4 - an optional blinded extension&#xD;
      arm (up to 3 months).&#xD;
&#xD;
      Stage 0. Baseline assessment: All consenting participants will complete 2 full days of&#xD;
      baseline diary (morning and evening) in order to become accustomed to completing the diary&#xD;
      regularly and to provide stable baseline data regarding breathlessness, symptoms and function&#xD;
      (as measured by activPALR actigraphy). At completion of the 2 days, the participant will be&#xD;
      reviewed, complete the remaining baseline assessments (questionnaires, measures and baseline&#xD;
      safety data), and will then be eligible to be randomised the first time.&#xD;
&#xD;
      Time period: Two full days (4 diary entries)&#xD;
&#xD;
      Stage 1. Randomisation #1: Randomisation to mane orally: placebo OR 8mg KapanolR OR 16mg&#xD;
      KapanolR. Twice daily diary. Participants randomised to KapanolR will also receive blinded&#xD;
      docusate with sennosides, while those randomised to placebo will receive identical placebo.&#xD;
      This is the primary outcome (end point) of the study.&#xD;
&#xD;
      Time period: 1 week&#xD;
&#xD;
      Stage 2. Randomisation #2: While continuing the arm assigned in Stage 1, add a randomisation&#xD;
      to mane orally: placebo OR 8mg KapanolR. Twice daily diary. Participants who were randomised&#xD;
      to placebo in Stage 1 and KapanolR in Stage 2 will have blinded docusate with sennosides&#xD;
      replace placebo.&#xD;
&#xD;
      Time period: 1 week&#xD;
&#xD;
      Stage 3. Randomisation #3: While continuing the arm assigned in Stages 1 and 2, add a third&#xD;
      randomisation to mane orally: placebo OR 8mg KapanolR. Twice daily diary. activPALR&#xD;
      accelerometer worn this week. Participants who were randomised to placebo in Stages 1 and 2&#xD;
      and KapanolR in Stage 3 will have blinded docusate with sennosides replace placebo.&#xD;
&#xD;
      Time period: 1 week&#xD;
&#xD;
      Stage 4. Extension (optional for each individual participant): Continue double blind&#xD;
      medications from Stages 1, 2 and 3 for up to three months. Diary one day each week. A blood&#xD;
      test at the end of the three months will be taken for total testosterone levels.&#xD;
&#xD;
      Time period: up to 3 months.&#xD;
&#xD;
      Target population: This study is for people with optimally treated people with mild, moderate&#xD;
      or severe chronic obstructive pulmonary disease (COPD).&#xD;
&#xD;
      Primary outcome and its assessment: Change from baseline average intensity of breathlessness&#xD;
      over the previous 24 hours, measured each morning on a 11 point numerical rating scale.&#xD;
&#xD;
      Significance: The study will answer several practical questions including whether opioids&#xD;
      have a net benefit in people with COPD in reducing refractory breathlessness, whether dose&#xD;
      increases beyond initial response provide a greater net benefit, the pattern of symptomatic&#xD;
      response in the days after successful titration, and the proportion of people who derive a&#xD;
      clinically meaningful symptomatic benefit at each dose level.&#xD;
&#xD;
      Analysis plan: All analyses will be conducted on an intention-to-treat basis. All analyses&#xD;
      will be conducted with Stata version 13.1. Missing data will be imputed using multiple&#xD;
      imputation with 50 resamples drawn. The primary comparisons on which the study is powered are&#xD;
      at the end of week 1: placebo compared to 8mg KapanolR daily; and placebo compared to 16mg&#xD;
      KapanolR daily. Change in breathlessness in the first week between these groups will be&#xD;
      evaluated using a random effects mixed model.&#xD;
&#xD;
      Sample size calculations: All calculations assume Type I (familywise error rate (FWER)) error&#xD;
      rate of 5% and Type II error rate of 20% (power of 80%) respectively. In order to account for&#xD;
      attrition of 20% by the end of week 1, the study will recruit 144*100/ (100-20) = 180&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    'Recruitment not possible given changes to trial criteria&#xD;
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline intensity of breathlessness over the previous 24 hours</measure>
    <time_frame>Week 1</time_frame>
    <description>Rated on a 0-10 numerical rating scale (NRS) in a diary each evening. The primary endpoint is the difference between placebo, morphine sulfate 8 mg, or 16 mg after the first treatment week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline unpleasantness of breathlessness over the previous 24 hours</measure>
    <time_frame>Week 3</time_frame>
    <description>Rated on a 0-10 numerical rating scale (NRS) in a diary each evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline intensity of breathlessness &quot;right now&quot;</measure>
    <time_frame>Week 3</time_frame>
    <description>Rated on a 0-10 numerical rating scale (NRS) in a diary each morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the intensity of breathlessness</measure>
    <time_frame>Week 1</time_frame>
    <description>In addition to the NRS ratings, the intensity of breathlessness is rated on a 0-10 modified Borg scale in a evening diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current medication use and compliance</measure>
    <time_frame>At study end for up to 15 weeks.</time_frame>
    <description>Collected in a diary in the evening, including of any rescue medication used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>At study end for up to 15 weeks.</time_frame>
    <description>Collected in a diary in the evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline physical activity using an accelerometer</measure>
    <time_frame>Week 3</time_frame>
    <description>Measured during two days at baseline and during at least five days of treatment week three.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in concurrent symptoms</measure>
    <time_frame>Week 1</time_frame>
    <description>Measured using the revised Edmonton Symptoms Assessment Scale (ESAS-r).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The modified Medical Research Council (mMRC) breathlessness scale</measure>
    <time_frame>At study end for up to 15 weeks.</time_frame>
    <description>Measures the functional impact of breathlessness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline serum testosterone level</measure>
    <time_frame>At the end of the 3 month follow-up stage, after up to 15 weeks.</time_frame>
    <description>To explore whether longer term morphine treatment is associated with decreased levels of testosterone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pharmacogenomic opioid blood profile</measure>
    <time_frame>Week 1</time_frame>
    <description>From the baseline sample, the UGT2B7*2 and *28 polymorphisms, P-glycoprotein (ABCB1 5SNPs in a haplotype block), the 5-hydroxytryptamine type 3B (HTR3B) gene rs7103572, and mu opioid receptor (A118G) polymorphisms will be measured. Interleukin 1ÃŸ, TNFalpha and Il-6 will be measured at baseline and at the end of the first treatment week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic/-kinetic blood samples</measure>
    <time_frame>Week 1</time_frame>
    <description>In a subset of 55 participants, blood parameters for morphine and its metabolites will be analysed (4 blood samples over 8 hours) at steady state of the treatment at the end of the week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline end-tidal carbon dioxide</measure>
    <time_frame>Week 3</time_frame>
    <description>Exhaled gas measured using a non-invasive capnometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pulse oximetry</measure>
    <time_frame>Week 3</time_frame>
    <description>Non-invasive measurement of the oxygen saturation, respiratory rate, and heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline sleep quality</measure>
    <time_frame>The final night of week 3</time_frame>
    <description>Twenty (20) participants at the Sydney and Adelaide sites will be invited to undertake a simple, non-invasive home sleep study using the ResMed ApneaLink Plus device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline sleep quality</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Rated on a 4 point Likert scale in a morning diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline sleep quality and sleep-related problems</measure>
    <time_frame>Week 3</time_frame>
    <description>The questionnaires used are the Epworth Sleepiness Scale, Leeds Sleep Questionnaire, and the Karolinska Sleepiness Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline bowel function index</measure>
    <time_frame>Week 1</time_frame>
    <description>Measure of the bowel function, during treatment with placebo / morphine sulfate 8 or 16 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline breathlessness-related quality of life</measure>
    <time_frame>Week 3</time_frame>
    <description>Measured on the CRQ-SAS Dyspnoea sub-scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline health-related quality of life</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Measured using the EQ-5D questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Life-space</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Life-Space is a measure of where a person goes, the frequency of going there, and the dependency in getting there.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Australian Karnofsky Performance Status</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>A score of 0 to 100 (in increments of 10) is assigned to participants based on their ability to undertake a range of daily tasks. The score gives an indication of the participant condition in terms of physical ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Hospital Anxiety and Depression Scale</measure>
    <time_frame>Week 3</time_frame>
    <description>A 14-item questionnaire used to measure anxiety and/or depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression of Change</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Participant-rated seven point scale of the perception of their change, specifically their improvement since the commencement of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinded patient preference to continue treatment</measure>
    <time_frame>At study end after up to 15 weeks.</time_frame>
    <description>Participants will be asked for their preference to continue at study exit ('Is this a therapy which, on balance, you would continue to take for your breathlessness?')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economy composite</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Data on all health care contacts including lenght of hospitalizations, emergency department visits, DRG codes, outpatient visits to general practitioner and community nurse, and date of death.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (0, 0, 8 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo during treatment week one and two and morphine 8 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (0, 8, 8 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo during treatment week one and morphine 8 mg per day week two and three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (0, 8, 16 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo week one, morphine 8 mg per day week two, and morphine 16 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (8, 8, 8 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 8 mg per day during all three treatment weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (8, 8, 16 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 8 mg per day week one and two and morphine 16 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (8, 16, 16 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 8 mg per day week one and morphine 16 mg per day week two and three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (8, 16, 24 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 8 mg per day week one, morphine 16 mg per day week two, and morphine 24 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (16, 16, 16 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 16 mg per day during all three treatment weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (16, 16, 24 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 16 mg per day week one and two, and morphine 24 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (16, 24, 24 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 16 mg per day week one and morphine 24 mg per day during week two and three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (16, 24, 32 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 16 mg per day week one, morphine 24 mg per day week two, and morphine 32 mg per day week three.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine sulfate</intervention_name>
    <description>Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.</description>
    <arm_group_label>Morphine sulfate (0, 0, 8 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (0, 8, 16 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (0, 8, 8 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (16, 16, 16 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (16, 16, 24 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (16, 24, 24 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (16, 24, 32 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (8, 16, 16 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (8, 16, 24 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (8, 8, 16 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (8, 8, 8 mg)</arm_group_label>
    <other_name>Kapanol(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Physician diagnosed COPD confirmed by spirometry, defined as a prior&#xD;
             post-bronchodilator FEV1/FVC &lt; 0.7 in accordance with the GOLD 2014 criteria&#xD;
&#xD;
          -  On stable medications relating to the optimal treatment of COPD or its symptomatic&#xD;
             management over the prior week except routine &quot;as needed&quot; medications.&#xD;
&#xD;
          -  Breathlessness of a level two (2) or higher on the modified Medical Research Council&#xD;
             (mMRC) dyspnoea scale&#xD;
&#xD;
          -  English speaking with sufficient reading and writing ability to complete the study&#xD;
             questionnaires&#xD;
&#xD;
          -  Assessed as competent (using SLUMS score of 27 for high school, and 25 for less than&#xD;
             high school)&#xD;
&#xD;
          -  Able and willing to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On regularly prescribed opioid medications, including codeine preparations at or above&#xD;
             8mg oral morphine equivalent daily in the previous seven (7) days.&#xD;
&#xD;
          -  History of adverse reactions to any of the study medications or constituents in the&#xD;
             placebo;&#xD;
&#xD;
          -  Australian-modified Karnofsky performance score (AKPS) less than 50 at the beginning&#xD;
             of the study.&#xD;
&#xD;
          -  Respiratory or cardiac event in the previous one week (excluding upper respiratory&#xD;
             tract infections). Illness must have resolved completely prior to baseline evaluation,&#xD;
             as judged by the person's treating physician.&#xD;
&#xD;
          -  Evidence of respiratory depression with resting respiratory rate &lt;8/min.&#xD;
&#xD;
          -  Documented central hypoventilation syndrome.&#xD;
&#xD;
          -  Chronic alcoholism, or previous or recent history of substance misuse.&#xD;
&#xD;
          -  Uncontrolled nausea, vomiting or evidence of a gastrointestinal tract obstruction.&#xD;
&#xD;
          -  Renal dysfunction with creatinine clearance calculated (MDRD) less than 20 mls/minute.&#xD;
&#xD;
          -  Evidence of severe hepatic impairment defined as transaminases or bilirubin &gt;4x normal&#xD;
             (Excluding Gilbert's syndrome)&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David C Currow, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flinders University</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Flinders University</investigator_affiliation>
    <investigator_full_name>David Currow</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

